Every 10-Q that SOLITRON DEVICES INC (SODI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SODI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SODI filings page.
Solitron Devices Inc. (SODI) reported net sales of $5.657 million for the three months ended August 31, 2026, up 42% from $3.986 million a year earlier. Net income was $1.298 million, compared with a $234,000 net loss. Gross profit was $2.748 million, versus $835,000.
For the six months ended August 31, 2026, sales were $11.093 million, up 66% from $6.686 million, and net income was $2.288 million versus a $570,000 net loss. Operating cash flow was $3.601 million, compared with $777,000. Backlog was $24.112 million as of August 31, 2026, versus $18.642 million one year earlier; management attributed the increase primarily to a large MEI order received during the quarter. Cash and cash equivalents were $7.357 million as of August 31, 2026.
RTX, ConMed Linvatec and L3 Harris accounted for 74% of six-month sales. Management said disclosure controls were appropriately designed, but there was insufficient evidence to test whether they operated effectively as of August 31, 2026, to remediate a previously reported material weakness. The company recorded $200,000 of professional fees related to pursuing strategic alternatives.
Solitron Devices, Inc. reported a strong turnaround for the three months ended May 31, 2026. Net sales were $5,436,000, up 101% from $2,700,000 a year earlier, driven by higher backlog and scheduled deliveries. Gross profit rose to $2,465,000, with gross margin improving to 45% from 14%.
Operating income was $1,535,000 versus a prior-year operating loss of $378,000. Net income reached $990,000, compared with a net loss of $336,000, and basic and diluted EPS were $0.46. Operating cash flow was $2,171,000, lifting cash and cash equivalents to $6,036,000 and working capital to $10,812,000.
Backlog at May 31, 2026 was $23,341,000, up 28% year over year, although net bookings for the quarter declined 48%. The contingent consideration liability related to the MEI acquisition increased to $1,119,000 due to higher MEI backlog. Management notes a previously identified material weakness in internal control over financial reporting remains, as new controls had not operated long enough to demonstrate effectiveness.
Solitron Devices, Inc. reported much stronger quarterly results for the three months ended November 30, 2025, with net sales rising to $5.0M from $3.4M a year earlier. Quarterly net income increased to $653K, or $0.31 per share, compared with $266K and $0.13 per share, helped by higher volumes and better gross margins.
Bookings were very strong at $13.9M and backlog more than doubled to $27.5M, driven largely by a major AMRAAM program order from the largest customer. Over the first nine months, net sales grew modestly to $11.7M but net income fell to $83K from $872K as earlier quarters absorbed higher material costs and tariffs. The company ended the quarter with $3.6M in cash, a new $1.65M long‑term investment, total assets of $25.7M, and stockholders’ equity of $19.0M.
Solitron Devices Inc. reported interim results showing continued operational activity from its recent acquisition of Micro Engineering, Inc. (MEI) and routine financial movements across cash, inventory and debt. The company recorded $42,000 of interest income from an investment and disclosed loan principal balances of $2,480,000 and $1,361,000 tied to property and acquisition financing. Sales remain meaningfully linked to U.S. government end-products, representing about 41% of revenue for the most recent quarter. The board approved equity actions including a $225,000 immediate stock grant and a repurchase program that bought 14,000 shares for about $63,000. Inventory concentrations at distributors and supplier concentration (one vendor ~39% of materials) are disclosed as operational risks.